Targeted Therapy for Myelofibrosis: How It Aims to Shrink the Spleen and Ease Symptoms

She had started ordering half portions. Not to lose weight, she told the nurse, but because her stomach felt full after six bites, and there was a dull ache under her left ribs that made lying on that side impossible. The blood tests had already spoken. The bone marrow biopsy had confirmed it. Now she was sitting across from a hematologist hearing the phrase targeted therapy for myelofibrosis and wondering how it works when the problem seems to be scar tissue in her bones, not a switch that can be flipped.

That question is the right one, and the answer is more interesting than a drug name. Myelofibrosis is driven by a signal that never turns off. The medicines built for it don’t repair the marrow; they turn the volume down on that signal.

What follows is what that means for the spleen, for the sweats and the exhaustion, for blood counts, and for the honest limits of what these medicines can do.

What is myelofibrosis, and why does the spleen get so big?

Bone marrow is the spongy tissue inside your bones where blood cells are made. In myelofibrosis, that tissue is gradually replaced by fibrous scar, so the marrow loses its ability to keep up. The condition belongs to a family called myeloproliferative neoplasms, chronic blood cancers in which the marrow makes too many of certain cells before it wears out. According to MedlinePlus, primary myelofibrosis affects roughly 1 in 500,000 people worldwide and is most often diagnosed between the ages of 50 and 80.

Most cases trace back to an acquired mutation in one of three genes: JAK2, CALR or MPL. About half of people carry the JAK2 change. Whichever gene is involved, the result is the same: a growth signal inside the cell that stays switched on when it should be resting.

The spleen enters the story because it is a backup factory. When marrow can no longer produce enough blood, the spleen and, to a lesser extent, the liver step in, a process called extramedullary hematopoiesis, which simply means blood production outside the marrow. The spleen also filters out the misshapen cells the failing marrow releases. Doing both jobs, it grows. A healthy spleen is about the size of a fist and sits tucked behind the ribs; in myelofibrosis it can extend well below the rib cage and press on the stomach. That pressure explains the early fullness, the left-sided ache and the unintended weight loss so many people describe before diagnosis.

Myelofibrosis can arise on its own, called primary, or develop years after polycythemia vera or essential thrombocythemia, two related conditions. The treatment logic is broadly the same for both.

Targeted therapy for myelofibrosis: how it works inside the cell

Traditional chemotherapy damages any cell that divides quickly. Targeted therapy, by contrast, is designed to interfere with one specific molecule that the disease depends on. In myelofibrosis that molecule is a family of enzymes called Janus kinases, abbreviated JAK.

Think of a JAK enzyme as a relay runner. Cytokines, the chemical messengers your body uses to coordinate blood production and inflammation, arrive at the cell surface and hand the baton to JAK, which passes it to proteins called STATs, which carry it into the nucleus with the instruction to grow and divide. In healthy marrow the relay runs only when a cytokine shows up. In myelofibrosis the JAK2, CALR and MPL mutations all end up jamming this same relay in the on position. The cell behaves as though it is being told to multiply, constantly.

JAK inhibitors are small molecules that fit into the pocket where the enzyme draws its energy, blocking the handoff. Two things follow. The overactive cells slow their proliferation, and the cells stop pumping out the excess inflammatory cytokines that had been driving fever, sweats and muscle wasting.

What these medicines do not do matters just as much. They do not correct the mutation. In most people they do not eliminate the abnormal clone of cells, and the scar tissue already laid down in the marrow largely remains. The closest everyday comparison is turning down a thermostat that is stuck on high: the house cools, life becomes comfortable again, but the faulty wiring is still in the wall. That is why the Mayo Clinic and other major centers describe these medicines as treatments that manage symptoms and spleen size rather than remove the disease.

How does quieting the JAK pathway shrink the spleen and ease symptoms?

The spleen shrinks for two reasons. Fewer cells are dividing inside it, and the cytokine storm that recruited it into overtime has quieted. Clinicians track the change in two ways: by feeling how many centimeters the spleen edge extends below the left rib margin, and, in trials, by measuring its volume on MRI or CT. The pivotal randomized trial of the first JAK inhibitor set the bar at a 35% reduction in spleen volume at 24 weeks, a figure that translates to roughly halving the palpable length below the ribs. That threshold has become the benchmark against which every newer agent is judged.

Symptom relief follows a separate but related route. The so-called constitutional symptoms of myelofibrosis, meaning drenching night sweats, fever without infection, intense itching, bone pain, appetite loss and the deep fatigue that sleep doesn’t touch, are largely the work of circulating cytokines such as interleukin-6 and tumor necrosis factor. These molecules are not side effects of the enlarged spleen; they come from the disease itself. Blocking JAK1, which most agents in the class do alongside JAK2, dials down their production directly.

Because the two effects run on partly separate tracks, one can arrive without the other. Some people feel their sweats stop within weeks while the spleen barely budges; others see a spleen response with lingering fatigue. Hematologists use a standardized ten-item questionnaire, the myelofibrosis symptom assessment form, to score symptoms before treatment and at each visit, so improvement is measured rather than guessed.

In the placebo-controlled trial cited above, differences in symptom scores between treated and untreated groups were apparent within the first month, which is why your team may ask how you feel long before they expect to see change on a scan.

Who is usually offered a JAK inhibitor, and who is usually asked to wait?

Myelofibrosis is not one disease at one speed. Hematologists sort people into risk groups using scoring systems, most commonly the International Prognostic Scoring System and its dynamic version, DIPSS-plus. These weigh age, hemoglobin level, white cell count, the percentage of immature cells called blasts in the blood, the presence of constitutional symptoms, platelet count, transfusion need and chromosome findings. The result is a category from low to high risk.

People most likely to be offered targeted therapy are those with an enlarged spleen that causes pain or early fullness, those with troublesome constitutional symptoms, or those whose risk score is intermediate or high. The medicine is aimed at what is bothering them, which is the point.

Watchful waiting is genuinely a treatment plan, not neglect. Someone with low-risk disease, a modest spleen and no symptoms gains little from a daily medicine whose main effects are on symptoms and spleen, while still taking on its side effects. The Mayo Clinic describes regular monitoring without medication as the standard approach in that situation.

Blood counts shape the choice within the class. Because JAK2 also carries the normal signal for making red cells and platelets, inhibiting it can lower both. Someone with a very low platelet count or transfusion-dependent anemia may be steered toward an agent whose design was studied in those circumstances, or toward supportive care first. Active infection, pregnancy and certain liver or kidney problems also prompt a pause.

Younger, fitter people with higher-risk disease are usually assessed for allogeneic stem cell transplant, a donor transplant that replaces the marrow. A JAK inhibitor is often used beforehand to shrink the spleen and improve fitness, then stopped around the transplant. Every one of these choices sits with the treating hematologist, who has the full picture.

How well does targeted therapy work? What the evidence actually shows

Here is the honest version. In the randomized, placebo-controlled trial of the first JAK inhibitor, indexed on PubMed, about two in five people on the medicine reached the 35% spleen-volume reduction at 24 weeks, compared with fewer than one in a hundred on placebo. A similar proportion had their total symptom score at least halved. Those are class-defining numbers, and every later agent has been measured against the same endpoints.

What the numbers also say is that the majority did not reach that spleen threshold. Many of them still had smaller but meaningful shrinkage and clear symptom relief, which is why clinicians look at the whole picture rather than a single cutoff. Response is a spectrum, not a pass or fail.

Durability is the harder conversation. Long-term follow-up studies show that spleen and symptom responses can last for years, but they also show that a substantial share of people eventually lose response or stop because of side effects. When that happens, teams consider switching to another agent in the class, adding a second medicine, entering a clinical trial or moving toward transplant.

Does targeted therapy change the disease itself? The evidence is mixed and worth stating plainly. Pooled analyses of trial participants suggest people treated earlier lived longer than those who crossed over later, which many hematologists interpret as a real survival effect. Yet fibrosis in the marrow rarely reverses in a major way, the mutated clone usually persists, and the risk of progression to acute leukemia does not appear to be eliminated. The most careful summary is that these medicines reliably make people feel and function better, may extend life, and do not remove the underlying disease. Donor transplant remains the only approach with the potential for long-term disease control.

What do the different JAK inhibitors for myelofibrosis have in common, and how do they differ?

Four JAK inhibitors are approved in the United States for myelofibrosis. All share the core mechanism described above, and all share the same principal weaknesses: they can lower red cells and platelets, and they can raise infection risk. Where they differ is in which enzymes beyond JAK2 they touch, and that shapes who might be considered for which.

The first approved agent, ruxolitinib, blocks both JAK1 and JAK2. Fedratinib is more selective for JAK2. Pacritinib also inhibits an enzyme called IRAK1, part of the innate immune signaling that fuels inflammation, and it was studied specifically in people with very low platelet counts. Momelotinib adds inhibition of ACVR1, a receptor that controls hepcidin, the liver hormone that locks iron away from red cell production; in principle, lowering hepcidin frees iron and may support hemoglobin. These are mechanistic distinctions, not rankings. None of them is offered as a recommendation here, and the evidence for each is something your hematologist weighs against your counts, prior treatments and other conditions.

A second wave of targeted approaches is under investigation, often in combination with a JAK inhibitor: BET inhibitors that alter how inflammatory genes are read, BCL-xL blockers that remove a survival signal from abnormal cells, telomerase inhibitors, and agents aimed directly at the fibrosis. None has established a place in routine care, and none should be assumed effective until randomized data say so. If your team mentions a clinical trial, that is the setting in which these belong.

Two practical points unite the class. Taking the medicine consistently matters, because the signal returns quickly when it is withdrawn. And interactions with common drugs that share liver enzymes are frequent, so every new prescription, including antifungals and some antibiotics, deserves a pharmacist’s check.

What do the first days and weeks on treatment usually look like?

Before the first dose, expect a baseline: a physical exam with the spleen edge marked in centimeters, a full blood count, a symptom questionnaire and sometimes an ultrasound or MRI. This is the yardstick everything later is measured against.

The first change most people notice is not in the spleen. Night sweats often lighten and itching eases within the first weeks, and appetite may return as the cytokine drive falls. In the placebo-controlled trial referenced earlier, symptom scores separated from placebo by the fourth week. Fatigue tends to be slower; it has more causes than cytokines alone, including anemia.

Weeks four through twelve are the period of closest watching. Hemoglobin and platelets typically fall in the first two to three months, reach their lowest point and then stabilize, a pattern documented in the same trial. Your team will draw blood frequently during this window, may adjust the treatment plan in response, and may arrange a transfusion if the dip is steep. This is expected biology, not a sign that something has gone wrong, and it is one reason people are asked not to skip early appointments.

Spleen change is usually measurable by around twelve weeks and formally assessed at 24, the interval trials use. Some people feel the difference sooner when they can finish a meal or lie on their left side again.

One caution deserves its own paragraph. Stopping a JAK inhibitor abruptly can produce a withdrawal syndrome: symptoms rebound within days, sometimes with fever and rapid spleen regrowth, and occasionally more seriously. Any pause, whether for surgery, illness or side effects, should be planned with the prescribing team rather than improvised. Keeping a simple diary of sweats, appetite, itch and energy gives your clinician far better data than memory at a clinic visit.

What side effects should you expect, and how are they monitored?

The side effects of JAK inhibitors are, for the most part, the mechanism working in places you would rather it didn’t. JAK2 carries the normal signals from erythropoietin and thrombopoietin, the hormones that instruct marrow to make red cells and platelets. Block the enzyme and both can fall. Anemia may bring breathlessness on stairs and a heavier fatigue; low platelets show up as easy bruising, nosebleeds or bleeding gums. The Cleveland Clinic lists both as the most common laboratory effects across the class, and both are why blood counts are checked so often early on.

JAK1 sits in the signaling chain of many immune cells, so infections are more likely. Shingles, urinary infections and pneumonia are the ones clinicians watch for most. Inactivated vaccines are generally encouraged; live vaccines are usually avoided, a decision for your team. A prior hepatitis B or tuberculosis exposure is often screened for before starting.

Other effects vary by agent. Weight gain and rising cholesterol are described with some. Dizziness and headache occur. Diarrhea, nausea and vomiting are more prominent with certain members of the class, and one agent carries a specific warning about thiamine (vitamin B1) deficiency, which can affect the brain; people on it have thiamine levels checked and are told to report confusion, unsteady walking or eye movement problems immediately. Non-melanoma skin cancers appear more often in people on long-term JAK inhibition, so sun protection and periodic skin checks become part of routine care.

Monitoring is therefore not optional overhead. It typically combines frequent blood counts in the first months, a review of symptoms and spleen size at each visit, lipid checks, skin surveillance and a low threshold for investigating fever. The pattern eases once counts settle, but it never fully stops while treatment continues.

Targeted therapy vs other myelofibrosis treatment options: how do they compare?

People often arrive asking which single treatment is the most effective. The more useful question is which treatment is aimed at the problem you actually have. Each approach below addresses a different target, and many people move between them over the course of the disease.

Approach	What it aims to do	Usually considered when	Main trade-offs
Watchful waiting	Monitor without medicine	Low-risk disease, small spleen, few symptoms	Requires regular visits; symptoms may emerge later
JAK inhibitor	Shrink spleen, reduce cytokine-driven symptoms	Symptomatic spleen or constitutional symptoms; intermediate or high risk	Anemia, low platelets, infections; does not remove the disease
Allogeneic stem cell transplant	Replace the marrow with a donor’s	Higher-risk disease in people fit enough for the procedure	Substantial short-term risk, graft-versus-host disease; the only option with potential for long-term disease control
Supportive treatments	Correct anemia or low counts	Symptomatic anemia, transfusion dependence	Transfusions, erythropoiesis-stimulating agents, androgens or immunomodulators each have limits and side effects
Spleen radiation or splenectomy	Reduce spleen size directly	Painful spleen not responding to medicine, or select transplant candidates	Radiation effect is temporary; surgery carries bleeding, clot and infection risk
Clinical trials	Test new targets or combinations	Loss of response, or when standard options are limited	Uncertain benefit by definition; close monitoring built in

Two things stand out. A JAK inhibitor is the workhorse for symptoms and spleen, but it does not treat anemia and may worsen it, so supportive measures often run alongside. And transplant is the only row that changes the underlying disease, which is why fitter people with higher-risk scores are assessed for it early, sometimes with a JAK inhibitor used as a bridge to get them there in better shape. The Mayo Clinic and Johns Hopkins both frame the decision this way: symptom control for most, transplant for the subset who can tolerate it.

What are the signs that myelofibrosis is progressing?

Progression is something your team measures, not something you are expected to diagnose at home. Still, knowing what they are looking for makes the blood test results and the questions at each visit easier to follow.

The laboratory markers come first. A rising percentage of blasts, the immature cells that a healthy marrow keeps inside, in the circulating blood is the change hematologists take most seriously, because a sustained level above a defined threshold signals transformation to acute myeloid leukemia. Published estimates cited by the Cleveland Clinic put that transformation at roughly one in ten to one in five people over the course of the disease. Falling hemoglobin that begins to need transfusions, platelet counts sliding despite stable treatment, and white cell counts drifting sharply in either direction are the other numeric signals.

The physical markers are the ones you may notice. A spleen that grows again after having shrunk, or that becomes newly painful, suggests the medicine is no longer holding it. The return of drenching sweats, unexplained fevers, bone pain or weight loss after a period of relief tells the same story from a different angle. New shortness of breath at rest can reflect either anemia or, less commonly, blood-making tissue lodging in the lungs.

None of these alone proves progression. Infections, other medicines and simple missed doses can mimic several of them, which is why your team responds to a pattern rather than a single result. What they will do is repeat counts, sometimes repeat the marrow biopsy, and re-run the risk score. If it has climbed, the conversation may turn to switching agents, transplant evaluation or a trial. The right move on your side is simpler: report what has changed, when it started, and whether any doses were missed.

What is the 5-year survival rate for myelofibrosis? An honest answer about life expectancy

It is the question almost everyone types into a search box after diagnosis, and the single number that comes back is almost always misleading. Myelofibrosis life expectancy varies more widely between risk groups than nearly any other blood cancer, so an average across all patients describes almost no individual patient.

The scoring systems described earlier exist precisely to replace that average with something personal. Someone in the lowest DIPSS-plus category, with normal hemoglobin, no blasts in the blood, no symptoms and a favorable chromosome pattern, faces an outlook measured in many years, often more than a decade. Someone in the highest category, with transfusion dependence, circulating blasts and adverse chromosome changes, faces a far shorter horizon. The spread between those groups is the honest answer, and your hematologist can tell you which group your results place you in and what the published data say about it.

Three cautions apply to any figure you are given. The estimates come from cohorts diagnosed before targeted therapy was widely available, so they may understate current outcomes. They are medians, meaning half of people did better than the number and half did worse. And they describe groups, not the person sitting in the chair, whose age, other conditions, response to treatment and transplant eligibility all shift the picture.

Whether JAK inhibitors themselves lengthen life is, as noted earlier, supported by pooled analyses but not proven by a trial designed for that purpose. Transplant can change the trajectory entirely for those who are candidates, at the cost of real short-term risk. This article deliberately does not print a percentage, because the responsible way to receive one is from a clinician who knows your numbers and can explain what they do and do not mean.

What people often get wrong about how targeted therapy for myelofibrosis works

Misunderstandings about these medicines are common enough that hematologists hear the same ones weekly. Correcting them changes how people use their treatment.

The first is that targeted therapy is a gentle form of chemotherapy. It is not chemotherapy at all; it blocks one enzyme rather than attacking dividing cells broadly, which is why hair loss is not a typical effect. But it is not gentle either. Low blood counts and infections are real, and monitoring is not optional.

The second is that a JAK inhibitor dissolves the scar tissue. In most people it does not. The marrow fibrosis stays roughly where it was; what changes is the inflammatory signal and the spleen. Expecting a biopsy to look normal after a year sets people up for disappointment about a treatment that is otherwise doing its job.

The third is that if the spleen has not shrunk by the trial benchmark, the medicine has failed. Response is a spectrum. A smaller reduction paired with sleeping through the night and finishing meals is a meaningful outcome, and clinicians judge the whole picture.

The fourth is that missing a few days is harmless. The signal these drugs suppress returns within days of withdrawal, and abrupt stopping can trigger a rebound with fever and rapid spleen regrowth. Pauses need a plan.

The fifth is that targeted therapy treats anemia. It frequently does the opposite, at least at first, because the same enzyme carries the red cell signal. Anemia is usually managed with separate measures.

The sixth is that a good response means transplant is off the table. For people who are candidates, a JAK inhibitor often serves as the bridge to transplant rather than a replacement for it. And the last: once symptoms settle, monitoring can lapse. Progression is caught in blood counts long before it is felt.

Questions to ask your care team

A hematology appointment moves quickly, and the questions you meant to ask have a way of surfacing in the parking lot. Writing them down beforehand shifts the conversation from what the clinician remembers to say toward what you actually need to know. These are the ones that tend to matter most, in roughly the order they arise.

• Which risk group do my results place me in, and which factors drove that score?
• What is the specific goal of this treatment for me: spleen size, symptoms, both, or preparing for transplant?
• How will you measure whether it is working, and when should we expect to see change?
• How often will my blood counts be checked in the first three months, and what would prompt a change of plan?
• If my hemoglobin or platelets fall, what are the options for managing that alongside treatment?
• Am I a potential candidate for a stem cell transplant, now or later, and when would that be reassessed?
• Which vaccines should I have before or during treatment, and which should I avoid?
• What medicines, supplements or foods interact with this treatment, and who should I check with before starting anything new?
• What should I do if I become ill, need surgery or cannot take the medicine for a few days?
• What symptoms should make me call the same day, and what number do I use out of hours?
• Are there clinical trials that would suit my situation, and how would I learn about them?
• How will we know if the disease is progressing, and what would the next options be?

Bring a family member or friend if you can. Two sets of ears retain more, and the person who lives with you often notices changes in energy and appetite that you have stopped registering yourself.

When to call your doctor

Most of life on a JAK inhibitor is routine: blood draws, questionnaires, a clinician’s hand checking the spleen edge. A few situations are not routine and should not wait for the next scheduled visit. Your team will give you a number to use, including out of hours; the point of this section is to make sure you use it.

Call the same day, or seek urgent care, for a fever or shaking chills, because infection risk is raised and low white cells can blunt the usual warning signs. Do the same for bleeding that does not stop with pressure, black or bloody stools, blood in the urine, or a sudden crop of bruises or pinpoint red spots, all of which can signal a platelet count that has dropped too far. Sudden, severe pain under the left ribs, especially with pain at the tip of the left shoulder, needs emergency assessment; it can indicate a blocked blood vessel in the spleen or, rarely, a rupture.

Chest pain, new breathlessness at rest, or a swollen, painful calf may indicate a blood clot and warrant emergency evaluation. Confusion, an unsteady walk, or unusual eye movements should be reported immediately, particularly on the agent linked to thiamine deficiency. A painful blistering rash in a band on one side of the body is typically shingles, which is treated most effectively when caught early.

Less dramatic changes still deserve a call within a day or two: drenching sweats or fever returning after a period of relief, particularly if doses were missed; a spleen that feels bigger or newly tender; weight loss you did not intend; or fatigue that is clearly worsening. None of these should be judged at home. The decision about what they mean, and what to do next, belongs with the team who knows your counts.

Frequently asked questions

How well does targeted therapy work for myelofibrosis?

In the pivotal randomized trial of the first JAK inhibitor, about two in five people achieved a 35% reduction in spleen volume at 24 weeks and a similar share had their symptom score at least halved, compared with almost none on placebo. Many others had smaller but meaningful improvements. Responses can last years, though some people eventually lose benefit or stop because of low blood counts or infections.

What is the most effective treatment for myelofibrosis?

There is no single most effective treatment because different options target different problems. JAK inhibitors are the standard for shrinking the spleen and easing constitutional symptoms. Allogeneic stem cell transplant is the only treatment with potential for long-term disease control but carries substantial risk and suits a minority. Supportive measures address anemia. Your hematologist matches the approach to your risk score, counts and fitness.

What is the 5-year survival rate for patients with myelofibrosis?

No single figure applies, because outlook varies enormously by risk group. People in the lowest-risk category often live well over a decade after diagnosis, while those with high-risk features face a much shorter horizon. Most published estimates come from cohorts diagnosed before modern therapy and describe medians for groups, not individuals. Ask your hematologist what your own risk score suggests and how treatment may change it.

What are the signs that myelofibrosis is progressing?

Clinicians watch for a rising percentage of immature blast cells in the blood, falling hemoglobin that starts to need transfusions, declining platelets, a spleen that regrows or becomes painful, and the return of night sweats, fever, bone pain or weight loss after a period of relief. These are assessed as a pattern with repeat blood counts and sometimes a marrow biopsy, never from one result alone.

Are JAK inhibitors for myelofibrosis a type of chemotherapy?

No. Chemotherapy damages any rapidly dividing cell, whereas JAK inhibitors block one specific enzyme that the disease relies on. That is why hair loss is not a typical effect. They are not free of side effects, though: because the same enzyme carries normal blood-making signals, anemia and low platelets are common, and infection risk is raised, so regular monitoring is essential.

How long does it take for the spleen to shrink on targeted therapy?

Symptom relief such as fewer night sweats often comes first, within the first weeks. Spleen shrinkage is usually measurable by around twelve weeks and is formally assessed at 24 weeks, the interval used in clinical trials. Some people feel the difference sooner when they can finish a meal or lie on their left side comfortably again. Timelines vary, and your team will set expectations for your situation.

Does targeted therapy help with anemia in myelofibrosis?

Usually not, and it can worsen anemia at first, because JAK2 also carries the signal for making red cells. Hemoglobin typically dips in the first two to three months before stabilizing. Anemia is generally managed with separate measures such as transfusions or other medicines. One newer agent in the class also blocks a pathway that regulates iron availability, but whether that suits you is a decision for your hematologist.

Can I stop my JAK inhibitor once I feel better?

Not without a plan from your prescribing team. The signal these medicines suppress returns within days of withdrawal, and abrupt stopping can cause symptoms to rebound quickly, sometimes with fever and rapid spleen regrowth. If you need to pause for surgery, illness or side effects, your team can manage the transition safely. Feeling well is a sign the treatment is working, not that the disease has gone.

What happens if targeted therapy stops working?

Loss of response is recognized when the spleen regrows, symptoms return or counts deteriorate despite consistent treatment. Options your team may consider include switching to a different JAK inhibitor with a distinct enzyme profile, adding a second medicine, evaluating for stem cell transplant if you are a candidate, or joining a clinical trial. The right choice depends on your counts, risk score and overall health.

What other myelofibrosis treatment options exist besides JAK inhibitors?

Watchful waiting is appropriate for low-risk disease without symptoms. Allogeneic stem cell transplant can offer long-term disease control for fitter people with higher-risk disease. Supportive treatments include transfusions, erythropoiesis-stimulating agents, androgens and immunomodulating medicines for anemia. Spleen radiation or splenectomy are used selectively for a painful spleen that resists medicine. Clinical trials test newer targets, often combined with a JAK inhibitor.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.